Tetrodotoxin
Sponsors
Wex Pharmaceuticals Inc.
Conditions
CancerChemotherapy-induced Neuropathic PainChemotherapy-induced Peripheral NeuropathyHealthyNeuropathic PainPainPeripheral NeuropathyTQT Study
Phase 1
Comparison Study of Liquid and Lyophilized Formulations of Subcutaneous Tetrodotoxin (TTX) in Healthy Volunteers
CompletedNCT01527734
Start: 2011-12-31Updated: 2012-02-08
A Phase 1, Single Ascending Dose, Randomized, Double-Blind, Placebo and Positive Controlled Study to Evaluate the Cardiovascular Effect of Tetrodotoxin in Healthy Adult Subjects
CompletedNCT04083833
Start: 2018-02-07End: 2018-03-24Updated: 2019-09-10
Phase 2
The Purpose of This Study is to Determine if Tetrodotoxin (TTX) is Effective in the Treatment of Pain Resulting From Chemotherapy Treatment
TerminatedNCT01655823
Start: 2012-07-31End: 2015-02-11Updated: 2018-10-30
A Randomized, Double-Blind, Placebo Controlled, Multicenter, Efficacy and Safety Trial of Single Cycle Tetrodotoxin in the Treatment of Chemotherapy Induced Neuropathic Pain
TerminatedNCT05359133
Start: 2022-04-19End: 2024-10-14Updated: 2025-02-20
Phase 3
Safety & Efficacy Study of Subcutaneous Tetrodotoxin for Moderate to Severe Inadequately Controlled Cancer-related Pain
CompletedNCT00725114
Start: 2008-04-30End: 2012-11-30Updated: 2014-07-09
Tetrodotoxin Open-label Efficacy and Safety Continuation Study
CompletedNCT00726011
Start: 2008-07-31End: 2012-07-31Updated: 2012-10-24